NON-SMALL CELL LUNG CARCINOMA
Clinical trials for NON-SMALL CELL LUNG CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new NON-SMALL CELL LUNG CARCINOMA trials appear
Sign up with your email to follow new studies for NON-SMALL CELL LUNG CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Experimental combo therapy trial halted early in cancer patients
Disease control TerminatedThis early-stage trial tested a new drug, TNO155, combined with either spartalizumab or ribociclib in 122 adults with advanced solid tumors like lung, head and neck, and colorectal cancers. The goal was to check safety and find the right dose. The study was terminated early, so r…
Matched conditions: NON-SMALL CELL LUNG CARCINOMA
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 22, 2026 12:07 UTC
-
New drug combo for lung cancer shows promise in early trial
Disease control TerminatedThis study tested a new drug combination (NT-I7 plus atezolizumab) in people with advanced non-small cell lung cancer that had not been treated before. The goal was to see if the combination could shrink tumors. The trial was stopped early, so final results are not available.
Matched conditions: NON-SMALL CELL LUNG CARCINOMA
Phase: PHASE2 • Sponsor: NeoImmuneTech • Aim: Disease control
Last updated Jun 22, 2026 12:05 UTC
-
Experimental cancer pill targets rare mutation, but trial halted early
Disease control TerminatedThis early-stage study tested an experimental oral drug called PRT7732 in 42 people with advanced solid tumors that have a SMARCA4 mutation. The goal was to check safety, find the right dose, and see if it shrinks tumors. However, the trial was terminated, so full results are not…
Matched conditions: NON-SMALL CELL LUNG CARCINOMA
Phase: PHASE1 • Sponsor: Prelude Therapeutics • Aim: Disease control
Last updated Jun 22, 2026 11:58 UTC
-
Experimental cancer pill fails to launch: early trial halted
Disease control TerminatedThis early-stage study tested an experimental oral drug called IK-595 in 75 adults with advanced solid tumors (like colorectal, pancreatic, or lung cancer) that have specific RAS or RAF gene mutations. The goal was to see if the drug is safe and how the body processes it. The stu…
Matched conditions: NON-SMALL CELL LUNG CARCINOMA
Phase: PHASE1 • Sponsor: Ikena Oncology • Aim: Disease control
Last updated Jun 02, 2026 11:40 UTC